Epigenetic modification of CD4+ T cells into Tregs by 5-azacytidine as cellular therapeutic for atherosclerosis treatment
Open Access
- 20 September 2024
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (9) , 1-11
Abstract
Recent research has explored the potential of the demethylating drug 5-azacytidine (Aza) as therapy for a range of diseases. However, the therapeutic efficacy of Aza for patients of atherosclerosis remains unclear. This study investigates the therapeutic application of Aza to atherosclerosis in order to elucidate the underlying mechanisms. We generated induced Tregs (iTregs) from CD4+ T cells by using Aza in vitro, and this was followed by the intravenous infusion of iTregs for the treatment of atherosclerosis. The adoptive transfer of Aza-iTreg significantly increased peripheral blood Treg cells, suppressed inflammation, and attenuated atherosclerosis in ApoE−/− mice. Furthermore, we observed a notable demethylation of the Forkhead box P3 (Foxp3)-regulatory T cell-specific demethylated region (TSDR) and an upregulation of Foxp3 expression in the CD4+ T cells in the spleen of the ApoE−/− mice following the transfer of Aza- iTregs. We also demonstrated that Aza converted naive CD4+ T cells into Tregs by DNA methyltransferase 1 (Dnmt1)-mediated Foxp3-TSDR demethylation and the upregulation of Foxp3 expression. Conversely, the overexpression of Dnmt1 in the CD4+ T cells attenuated the Aza-induced Foxp3-TSDR demethylation and upregulation of Foxp3 expression. Our results reveal that Aza converts naive CD4+ T cells into functional Tregs by inhibiting Dnmt1, and the transfer of Aza-iTregs suppresses atherosclerosis in mice.Keywords
This publication has 34 references indexed in Scilit:
- Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage?Nature Reviews Immunology, 2009
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- Regulatory T-Cell Immunity in AtherosclerosisTrends in Cardiovascular Medicine, 2007
- Role of Naturally Occurring CD4 + CD25 + Regulatory T Cells in Experimental AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Generation of HSP60-specific regulatory T cell and effect on atherosclerosisCellular Immunology, 2006
- Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412New England Journal of Medicine, 2006
- The immune response in atherosclerosis: a double-edged swordNature Reviews Immunology, 2006
- Natural regulatory T cells control the development of atherosclerosis in miceNature Medicine, 2006
- Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-selfNature Immunology, 2005
- Induction of a Regulatory T Cell Type 1 Response Reduces the Development of Atherosclerosis in Apolipoprotein E–Knockout MiceCirculation, 2003